About
Tumor Immunotherapy, Bispecific Antibodies, CAR T
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyChina
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
3
As Collaborator
3
Total Enrollment
368
By Phase
EARLY_PHASE1: 2PHASE1: 2PHASE1/PHASE2: 2
By Status
RECRUITING: 5UNKNOWN: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT07101705Collaborator
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
EARLY_PHASE1Recruiting
40 participants
Started: Sep 8, 2025 · Completed: Aug 1, 2028
NCT06891742Collaborator
Phase I Study of OriC902 in Treatment of Advanced HCC
PHASE1Recruiting
44 participants
Started: Feb 24, 2025 · Completed: Mar 31, 2028
NCT06271252Lead Sponsor
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
PHASE1Recruiting
81 participants
Started: Apr 3, 2024 · Completed: Apr 12, 2028
NCT06182696Lead Sponsor
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
PHASE1/PHASE2Recruiting
83 participants
Started: Oct 26, 2023 · Completed: Aug 31, 2028
NCT05652920Lead Sponsor
Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
PHASE1/PHASE2Recruiting
105 participants
Started: Dec 15, 2022 · Completed: Dec 31, 2026
Locations (1)
Headquarters
Shanghai, China
Map
Loading map...